세계의 표피 성장인자 수용체(EGFR) 억제제 시장 예측(-2030년)

According to Stratistics MRC, the Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market is accounted for $14.1 billion in 2024 and is expected to reach $31.4 billion by 2030 growing at a CAGR of 14.2% during the forecast period. Epidermal Growth Factor Receptor (EGFR) inhibitors are a class of medications that target the epidermal growth factor receptor, a protein found on the surface of cells. EGFR is involved in cell growth and division, and its overactivity is associated with the development and progression of certain types of cancer, particularly lung cancer and colorectal cancer. GFR inhibitors are used in the treatment of various cancers, either alone or in combination with other cancer therapies, such as chemotherapy or radiation therapy.

According to the NIH, the new cases of various types of major cancers, such as lung cancer, colorectal cancer, and breast cancer, in the US have increased significantly in recent years. In 2020, an estimated 1.8 million new cases of cancer were diagnosed in the US, and 606,520 people will die from the disease.

Market Dynamics:

Driver:

Growing adoption of targeted therapies

The market is witnessing a surge in adoption of targeted therapies, reflecting an evolving treatment landscape. Targeted therapies offer precision in combating cancer by specifically targeting cancer cells, minimizing damage to healthy tissue. This paradigm shift is driven by advancements in research and development, alongside increasing understanding of molecular pathways driving cancer progression. With personalized treatment approaches gaining traction, the market is poised for substantial growth as it moves towards tailored therapies for individual patients.

Restraint:

Availability of alternative therapies

The market faces challenges in accommodating alternative therapies. Despite the effectiveness of EGFR inhibitors, alternative treatments like immunotherapy and targeted therapies pose competition. Additionally, resistance to EGFR inhibitors and adverse effects contribute to the complexity. Ensuring accessibility, affordability, and patient awareness of alternative therapies remain key hurdles. The market must adapt by integrating these therapies into treatment protocols and addressing patient-specific needs for optimal outcomes.

Opportunity:

Rising cancer rates

The market has seen a concerning trend of rising cancer rates. Despite advancements in treatment utilizing EGFR inhibitors, such as Erlotinib and Gefitinib, the incidence of cancer cases reliant on these therapies has increased. This may indicate either a growing prevalence of EGFR-driven cancers or potential resistance development in patients previously responsive to these drugs. Such trends underscore the need for continued research into cancer biology and the development of innovative therapeutic strategies.

Threat:

High cost of treatment

The market faces challenges due to high treatment costs, posing a barrier to accessibility for patients. Despite their efficacy in treating certain cancers, the financial burden associated with these inhibitors limits their widespread adoption. This cost factor underscores the need for collaborative efforts among stakeholders to develop more affordable options or explore avenues for subsidization to ensure equitable access to life-saving treatments.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the Market, causing disruptions in manufacturing, supply chains, and clinical trials. Lockdowns and restrictions hindered patient access to healthcare facilities, affecting diagnosis and treatment initiation. However, with the adoption of telemedicine and remote monitoring, some continuity was maintained. The market witnessed fluctuations in demand, with a shift towards prioritizing essential treatments. Despite challenges, ongoing research and development efforts persisted, aiming to address emerging needs and optimize therapeutic outcomes amidst the pandemic's challenges.

The combination therapies segment is expected to be the largest during the forecast period

The combination therapies segment is expected to be the largest during the forecast period. By targeting multiple pathways simultaneously, these therapies aim to enhance efficacy and overcome resistance mechanisms. Combinations of EGFR inhibitors with chemotherapy, immunotherapy, and other targeted agents are being explored, showing potential in various cancer types. Such approaches offer new avenues for personalized treatment regimens and may improve patient outcomes by addressing heterogeneous tumor profiles and adaptive resistance mechanisms.

The colorectal cancer segment is expected to have the highest CAGR during the forecast period

The colorectal cancer segment is expected to have the highest CAGR during the forecast period driven by advancements in targeted therapies. These inhibitors, such as cetuximab and panitumumab, have shown promising results in improving patient outcomes by inhibiting EGFR signaling pathways. With increasing prevalence of colorectal cancer globally, coupled with growing demand for personalized treatment approaches, the EGFR inhibitors market is poised for significant growth.

Region with largest share:

North America is projected to hold the largest market share during the forecast period driven by factors such as increasing cancer prevalence and advancements in targeted therapies. With a focus on precision medicine, these inhibitors play a crucial role in treating various cancers, including lung and colorectal cancer. Key players in the region continue to invest in research and development, aiming to introduce innovative therapies.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The region has witnessed a rise in the incidence of cancer, including lung cancer and colorectal cancer, which are often treated with EGFR inhibitors. Increasing awareness about cancer and the availability of screening programs have led to earlier detection of cancers, resulting in more patients being eligible for targeted therapies. Moreover, rising healthcare expenditure and awareness further bolster market growth, fostering a competitive landscape characterized by ongoing clinical trials and product launches.

Key players in the market

Some of the key players in Epidermal Growth Factor Receptor (EGFR) Inhibitors market include Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Amgen Inc, Eli Lilly and Company, OSI Pharmaceuticals Inc, Johnson & Johnson, Genentech, Inc, Pfizer, AstraZeneca PLC, Bayer AG, AbbVie, Bristol Myers Squibb, Teva Pharmaceutical Industries, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim and Regeneron Pharmaceuticals.

Key Developments:

In May 2023, Eli Lilly and Innovent Biologics, Inc. jointly announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for TYVYT(R) (sintilimab injection) in combination with bevacizumab and chemotherapy (pemetrexed and cisplatin) in patients with epidermal growth factor receptor (EGFR)-mutated non-squamous non-small cell lung cancer (NSCLC).

In September 2022, Novartis announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer (aBC)1.

Types Covered:

• Monoclonal Antibodies (mAbs)
• Tyrosine Kinase Inhibitors (TKIs)
• Combination Therapies
• Other Types

Drug Types Covered:

• Erlotinib
• Cetuximab
• Gefitinib
• Osimertinib
• Afatinib
• Other Drug Types

Mode of Administration Covered:

• Oral
• Intravenous

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Applications Covered:

• Non-Small Cell Lung Cancer (NSCLC)
• Pancreatic Cancer
• Colorectal Cancer
• Head and Neck Cancer
• Other Applications

End Users Covered:

• Hospitals
• Cancer Treatment Centers
• Academic & Research Institutes
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Epidermal Growth Factor Receptor (EGFR) Market, By Type

• 5.1 Introduction
• 5.2 Monoclonal Antibodies (mAbs)
• 5.3 Tyrosine Kinase Inhibitors (TKIs)
• 5.4 Combination Therapies
• 5.5 Other Types

6 Global Epidermal Growth Factor Receptor (EGFR) Market, By Drug Type

• 6.1 Introduction
• 6.2 Erlotinib
• 6.3 Cetuximab
• 6.4 Gefitinib
• 6.5 Osimertinib
• 6.6 Afatinib
• 6.7 Other Drug Types

7 Global Epidermal Growth Factor Receptor (EGFR) Market, By Mode of Administration

• 7.1 Introduction
• 7.2 Oral
• 7.3 Intravenous

8 Global Epidermal Growth Factor Receptor (EGFR) Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Hospital Pharmacies
• 8.3 Retail Pharmacies
• 8.4 Online Pharmacies

9 Global Epidermal Growth Factor Receptor (EGFR) Market, By Application

• 9.1 Introduction
• 9.2 Non-Small Cell Lung Cancer (NSCLC)
• 9.3 Pancreatic Cancer
• 9.4 Colorectal Cancer
• 9.5 Head and Neck Cancer
• 9.6 Other Applications

10 Global Epidermal Growth Factor Receptor (EGFR) Market, By End User

• 10.1 Introduction
• 10.2 Hospitals
• 10.3 Cancer Treatment Centers
• 10.4 Academic & Research Institutes
• 10.5 Other End Users

11 Global Epidermal Growth Factor Receptor (EGFR) Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Novartis AG
• 13.2 F. Hoffmann-La Roche Ltd
• 13.3 Merck & Co.
• 13.4 Amgen Inc
• 13.5 Eli Lilly and Company
• 13.6 OSI Pharmaceuticals Inc
• 13.7 Johnson & Johnson
• 13.8 Genentech, Inc
• 13.9 Pfizer
• 13.10 AstraZeneca PLC
• 13.11 Bayer AG
• 13.12 AbbVie
• 13.13 Bristol Myers Squibb
• 13.14 Teva Pharmaceutical Industries
• 13.15 Takeda Pharmaceutical Company Limited
• 13.16 Boehringer Ingelheim
• 13.17 Regeneron Pharmaceuticals